XM does not provide services to residents of the United States of America.

Philips shares climb 2.5% after top investor Exor boosts stake



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Philips shares climb 2.5% after top investor Exor boosts stake</title></head><body>

Adds details, context

AMSTERDAM, June 26 (Reuters) -Philips PHG.AS shares rosemore than 2.5% on Wednesday, a day after a U.S. Securities and Exchange Commission filing showedExor EXOR.AS, investment arm of Italy's Agnelli family, had increased its stake in the Dutch healthcare technology group.

According to the filing on Tuesday, Exor now owns 17.51% of Philips, up from 15.1%, strengthening its position as top investor of the group.

A spokesman for Netherlands-based Exor - which can further increase its stake in Philips to as much as 20% - declined to give details about the stake increase or any potential further share purchase.

Exor bought its initial 15.1% stake in Philips in Augustlast year, a move seen as a vote confidence in the Dutch company, which at that time was in the late stages of a huge product recall ongoing since2021.

Since then, Amsterdam-listed shares in Philips have jumped over 30%, also supported by a final deal on its sleep apnea machines reached with the U.S. government two months ago.

Exor, whose investments include manufacturing, media, fashion, sport and technology, has said it had agrowing interest in the healthcare industry.

CEO John Elkann, scion of the Agnelli family, said earlier this year in a letter to Exor shareholders that Philips had "leadership positions in highly attractive segments" and its management was "tackling head-on" the challenges it faced.

Exor is the controlling shareholder of companies including Ferrari RACE.MI and Serie A soccer club Juventus JUVE.MI, and is the single largest investor in automaker Stellantis STLAM.MI.

At 1010GMT, Philips shares were up2% at 24.34euros, outperforming the Dutch AEX .AEX blue chip index. Since the start of the year, Philips has gained almost 20% after surging57% in 2023. Those advances came after it lost 68% over the 2021-2022 period.



Reporting by Toby Sterling and Benoit Van Overstraeten in Amsterdam, Giulio Piovaccari in Milan; Editing by Louise Heavens and Bernadette Baum

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.